When is SABR the Preferred Treatment in Lung Cancer?
The clinical use of SABR for early stage non-small cell lung cancer has increased considerable during the last decade. In this webinar, current and future indication for SABR in this disease will be discussed. Treatment of patients with a higher risk of toxicity due to tumor location or presence of interstitial lung disease will be […]
SBRT as an Alternative for Surgery in Early Stage NSCLC
SBRT is now the standard treatment for patients with medically inoperable NSCLC. SABR is safe, effective and is associated with limited toxicity. These excellent results have led to the question whether SABR can also be used in medically operable NSCLC patients. In this webinar, after a short overview of the accomplishments of SABR in medically […]